Davarpanah, 206 patient spironolactone antiandrogen late treatment study: 78% lower hospitalization [p=0.0008] and 64% faster recovery [p=0.0001] https://c19p.org/davarpanah
copied to clipboard
Combination of Spironolactone and Sitagliptin Improves Clinical Outcomes of Outpatients with COVID-19: An Observational Study
et al., medRxiv, doi:10.1101/2022.01.21.22269322 (Preprint)
Prospective study of 206 outpatients in Iran, 103 treated with spironolactone and sitagliptin, showing lower hospitalization and faster recovery with treatment. spironolactone 100mg and sitagliptin 100mg daily.
|
risk of hospitalization, 78.3% lower, RR 0.22, p < 0.001, treatment 6 of 103 (5.8%), control 23 of 103 (22.3%), NNT 6.1, odds ratio converted to relative risk.
|
|
recovery time, 64.4% lower, relative time 0.36, p < 0.001, treatment 103, control 103.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Davarpanah et al., 21 Jan 2022, prospective, Iran, preprint, 9 authors, study period July 2021 - September 2021, average treatment delay 5.74 days, this trial uses multiple treatments in the treatment arm (combined with sitagliptin) - results of individual treatments may vary.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.